SIP
ZBIO

Stoneridge Investment Partners’s Zenas BioPharma ZBIO Stock Holding History

Stoneridge Investment Partners’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,955
Closed -$87K – 152
2025
Q1 		$87K Hold
10,955
– – 0.07% 98
2024
Q4 		$90K Buy
+10,955
New +$171K 0.03% 123

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Stoneridge Investment Partners's ZBIO Position: Q2 2025 in Review

Stoneridge Investment Partners sold out of Zenas BioPharma (ZBIO) in Q2 2025, closing a stake of 10,955 shares — an estimated $87K sold.

Stoneridge Investment Partners first reported a position in ZBIO in Q4 2024 and held it in 2 quarters. The position peaked at $90K in Q4 2024. 73 funds tracked by Wall St. Rank hold ZBIO as of Q2 2025.

  • Stoneridge Investment Partners reported no remaining Zenas BioPharma position as of Q2 2025 after selling out during the quarter.
  • Stoneridge Investment Partners sold 10,955 Zenas BioPharma shares in Q2 2025, an estimated $87K.
  • Stoneridge Investment Partners first reported a position in Zenas BioPharma in Q4 2024 and held it in 2 quarters.
  • Stoneridge Investment Partners's Zenas BioPharma position peaked at $90K in Q4 2024.
  • 73 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2025.

Based on Stoneridge Investment Partners's 13F filing for Q2 2025, filed 11 Aug 2025.